NCR1: A Protein Involved in NK Cell Function and Cancer Therapy

Target Name: NCR1

NCBI ID: G9437

NCR1

NCR1: A Protein Involved in NK Cell Function and Cancer Therapy

NCR1 (Natural killer cell p46-related protein) is a protein that is expressed in various cell types, including natural killer (NK) cells, which play a critical role in immune surveillance of the body. NK cells are a type of immune cell that have the ability to recognize and destroy infected or mutated cells, as well as cancer cells. The discovery and characterization of NCR1 has important implications for the development of new drugs and biomarkers for these diseases.

NCR1 is a member of the P46 family of proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain (NBO), a zinc finger, and a carboxylic acid loop. These domains are responsible for the protein's unique structure and function. NCR1 is a 24.1 kDa protein that consists of 216 amino acid residues.

NCR1 is expressed in various cell types, including NK cells, macrophages, and dendritic cells. It is highly expressed in NK cells, which are a type of immune cell that play a critical role in immune surveillance of the body. NK cells are able to recognize and destroy infected or mutated cells, as well as cancer cells. The ability of NK cells to recognize and destroy cancer cells makes them an attractive target for cancer therapy.

NCR1 has been shown to play a role in the regulation of NK cell function. NK cells are able to recognize and destroy infected or mutated cells through a process called phagocytosis. Phagocytosis is the process by which NK cells engulf and destroy foreign particles, including cancer cells. NCR1 is involved in the regulation of phagocytosis by the T-cell signaling pathway.

In addition to its role in NK cell function, NCR1 has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo and die as a normal part of the cell cycle. Apoptosis is a critical mechanism that helps to remove damaged or dysfunctional cells from the body, and it is important for maintaining tissue homeostasis and preventing the development of diseases.

NCR1 has also been shown to play a role in the regulation of cell signaling pathways, including the T-cell signaling pathway. The T-cell signaling pathway is involved in the regulation of T-cell development, activation, and proliferation, and is important for the immune response. NCR1 is involved in the regulation of T-cell signaling through its ability to interact with the protein PD-L1.

In conclusion, the discovery and characterization of NCR1 is important for the development of new drugs and biomarkers for cancer and other diseases. NCR1 is involved in the regulation of NK cell function, as well as the regulation of cell apoptosis and signaling pathways. The ability of NCR1 to interact with the protein PD-L1 makes it an attractive target for cancer therapy. Further research is needed to fully understand the role of NCR1 in these processes and to develop new treatments for cancer and other diseases.

Protein Name: Natural Cytotoxicity Triggering Receptor 1

Functions: Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis

The "NCR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets